Clinical trials: Varenicline
Smoking, Cigarette, Smoking Cessation
Health Systems Reach Interventions Project
This project seeks to identify ways to enhance the reach of evidence-based smoking cessation treatments among adult primary care patients who smoke daily and are not ready to start treatment at study enrollment.
- Trial name
- NCT04199117
- Testing
- Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- University of Wisconsin, Madison
Alcoholism, Nicotine Dependence
Varenicline and Alcohol in Inpatient Addictions Program (IAP)
The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates.
- Trial name
- NCT01169610
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Nicotine Dependence
Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
The purpose of this study is to look at brain function in order to understand how different treatments work to help people quit smoking.
- Trial name
- ConNicBrain (NCT01406223)
- Testing
- Varenicline, Bupropion, Nicotine patches
- Where
- 2 sites in United States
- Volunteers
- 282 people
- Sponsor
- Duke University
Smoking Cessation
Web-based Smoking Cessation Program for Tribal College Students
The purpose of this study is to test the effectiveness of a culturally-tailored Internet-based program that helps American Indian (AI) tribal college students quit smoking.
- Trial name
- NCT02050308
- Testing
- Internet-All Nations Breath of Life (I-ANBL), Honoring the Gift of Heart Health, Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®
- Where
- 2 sites in United States
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Won Choi, PhD, MPH
Tobacco Dependence
UW Quitting Using Intensive Treatment Study (QUITS)
This research will determine whether two highly promising modifications to varenicline treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce superior smoking outcomes when they are either used…
- Trial name
- QUITS (NCT03176784)
- Testing
- Varenicline, Nicotine patch
- Where
- 2 sites in United States
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Tobacco Use Cessation
Improving Varenicline Adherence and Outcomes in Homeless Smokers
the purpose of the study is to see if varenicline in combination with motivational counseling helps homeless cigarette smokers quit smoking.
- Trial name
- NCT00786149
- Testing
- Varenicline plus Motivational Interviewing counseling, Varenicline without counseling
- Where
- United States
- Volunteers
- 428 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Nicotine Dependence
Examination of Sleep, Smoking Cessation, and Cardiovascular Health
Most treatment-seeking smokers will fail in their attempts to quit smoking in the early days and weeks of quitting. Poor sleep (e.g., short duration) is an overlooked, but important nicotine withdrawal symptom that can affect up…
- Trial name
- NCT02941718
- Testing
- Sleep Advancement Counseling, General Health Information
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Nicotine Dependence
Varenicline for the Treatment of Smokeless Tobacco
Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco…
- Trial name
- CHANCHEW (NCT00813917)
- Testing
- varenicline
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Smoking
The Compliance of Varenicline With Short-massage
Research indicated that the relapse rate of smokers who attempted to give up smoking without drug and other assistance is up to 90-95% while the successful cessation rate may be improved a lot with assistance to quit smoking.
- Trial name
- CV-SM (NCT01656083)
- Where
- Germany
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- yu hong xia
Smoking Cessation
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
- Trial name
- NCT00483002
- Testing
- varenicline
- Volunteers
- 3,719 people
- Sponsor
- Pfizer
Smoking Cessation
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in…
- Trial name
- ASIA CHOICES (NCT00808015)
- Testing
- varenicline
- Where
- 97 sites in China, India and 2 more
- Volunteers
- 1,373 people
- Sponsor
- Pfizer
Stroke
Cost Free Pharmacotherapy for Smoking Cessation in Stroke Patients
This pilot study examined the effect of providing a 4 weeks of cost free quit smoking medications to smokers identified in a stroke prevention clinic who were interested in quitting smoking compared to providing a prescription…
- Trial name
- NCT01404546
- Testing
- cost free pharmacotherapy, usual care
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Recurrence, Smoking Cessation
Relapse Prevention With Varenicline
This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory.
- Conditions
- Recurrence, Smoking Cessation, Substance-Related Disorders
- Trial name
- 0815 (NCT00944554)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Nicotine Dependence, Transcranial Magnetic Stimulation
Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)
The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products.
- Conditions
- Nicotine Dependence, Transcranial Magnetic Stimulation, Vaping, Smoking Cessation
- Trial name
- V-TMS (NCT07145866)
- Testing
- Varenicline, Transcranial Magnetic Stimulation, Nicotine Cessation Counseling
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Smoking Cessation, Electronic Cigarette
Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers
Abstract Rationale. Electronic cigarette use is increasing at an exponential rate in Finland and internationally. The health consequences of vaporised aerosols in electronic cigarettes are largely unknown especially in a long…
- Trial name
- EFFECT (NCT03235505)
- Testing
- Nicotine, Varenicline Tartrate, Motivational Interview
- Where
- Finland
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Oulu
Tobacco Use Disorder
Efficacy of Varenicline for Smokeless Tobacco Use in India
This study, based in India, is testing the efficacy of varenicline to help smokeless tobacco users with cessation efforts.
- Trial name
- NCT01098305
- Testing
- Varenicline, Counseling
- Where
- India
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dry Eye Disease
Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).
- Trial name
- NCT03873246
- Testing
- OC-01 0.1% 0.6 mg/ml, OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Oyster Point Pharma, Inc.
Smoking Cessation
Varenicline Observational Investigation In The Cessation of Smoking
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support…
- Trial name
- CHOICES (NCT00669240)
- Testing
- Varenicline
- Where
- 52 sites in Belgium, Greece and 2 more
- Volunteers
- 567 people
- Sponsor
- Pfizer
Smoking Cessation, Genetic Predisposition
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)
Smoking is the leading cause of avoidable death in the world. Smoking is associated with the development of cardiovascular and respiratory diseases, as well as being considered a leading cause of cancer death.
- Trial name
- GENTSMOKING (NCT03362099)
- Testing
- Varenicline Tartrate or bupropion
- Where
- Brazil
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Smoking Cessation
Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
There are currently over 11 million cancer survivors in the U.S. and survival rates are increasing. Unfortunately, 10-30% of cancer patients are current smokers at the time of diagnosis, and many of these patients have elevated…
- Trial name
- NCT01871506
- Testing
- Standard Care (SC), Intensive Counseling (IC)
- Where
- 3 sites in United States
- Volunteers
- 303 people
- Sponsor
- Massachusetts General Hospital